e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Novel treatments for cough, asthma, COPD and bronchiectasis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies
Tatiana Molostova (Moscow, Russian Federation), Tatiana Molostova, Alexander Chuchalin, Sofia Skachilova, Elena Shilova, Yuriy Kalinin, Tamerlan Balaev, Irina Badygina, Alexander Solovyev
Source:
International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Session:
Novel treatments for cough, asthma, COPD and bronchiectasis
Session type:
Thematic Poster Session
Number:
3958
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tatiana Molostova (Moscow, Russian Federation), Tatiana Molostova, Alexander Chuchalin, Sofia Skachilova, Elena Shilova, Yuriy Kalinin, Tamerlan Balaev, Irina Badygina, Alexander Solovyev. Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies. Eur Respir J 2015; 46: Suppl. 59, 3958
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Interaction between aclidinium bromide and formoterol fumarate in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Combination study of tiotropium and olodaterol in human precision-cut lung slices
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Interaction between RPL554 and glycopyrronium bromide in small human airways
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
A comparison of beta
2
-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Pharmacologic bronchodilation response to salbutamol in COPD patients
Source: International Congress 2014 – Predictors
Year: 2014
Inhaled roflumilast and tadalafil supress airway reactivity and inflammation in ovalbumin-sensitized guinea pigs
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta
2
-agonists in dogs
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effectiveness of glycopyrronium bromide in the treatment of small airways dysfunction
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy
Source: Eur Respir Rev 2008; 17: 41-42
Year: 2008
Rapid corticosteroid effect on long-acting β
2
-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy
Source: Eur Respir J 2007; 30: Suppl. 51, 713s
Year: 2007
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept